The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Increase In Market Value Is Predicted For The Sogroya Market During The 2026–2030 Period?
Historical growth stemmed from the enhanced diagnosis of adult growth hormone deficiency, an expansion of endocrinology specialty care, increased availability of recombinant hormone therapies, growing awareness of adult GHD symptoms, and the adoption of injectable hormone replacement.
Expected growth throughout the forecast period stems from several factors, including a heightened demand for less complex hormone replacement methods, a greater emphasis on improving patients’ quality of life, the broadening availability of hormone therapy administered at home, increasing financial commitments towards long-acting biological treatments, and a growing inclination among physicians for once-a-week dosing schedules.
Key developments anticipated during the forecast timeframe involve the wider acceptance of long-acting growth hormone replacement therapies, an increasing need for weekly treatments for adult growth hormone deficiency, a stronger focus on enhancing patient adherence to prescribed treatments, the advancement and broader application of pegylated hormone technologies, and a more pronounced prioritization of patient convenience.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20358&type=smp
Which Growth Drivers Are Expected To Support The Sogroya Market Forward?
The rising need for hormone replacement therapy (HRT) is expected to propel the sogroya market’s expansion in the future. This medical approach involves replacing hormones such as estrogen and progesterone to alleviate issues stemming from menopause or hormonal discrepancies. The growing uptake of HRT can be attributed to the increasing occurrence of hormonal imbalances, enhanced understanding of its advantages, and progress in medical therapies, which collectively make it more attainable and successful for managing conditions like menopause and growth hormone deficiencies. Sogroya contributes to hormone replacement therapy through its once-weekly treatment for individuals with growth hormone deficiency, aiding in the restoration of normal growth hormone levels, betterment of physical function, and improvement of overall quality of life via a convenient and potent dosing schedule. As an illustration, in October 2025, the UK government body The National Health Service (NHS) reported that roughly 14.7 million hormone replacement therapy (HRT) items were prescribed in the most recent period, showing an 11% rise compared to 2023/24. Consequently, the increasing need for hormone replacement therapy is fueling the growth of the sogroya market.
What Are The Major Segment Categories Within The Sogroya Market?
The sogroya market covered in this report is segmented –
1) By Indication: Adult Growth Hormone Deficiency, Pediatric Growth Hormone Deficiency
2) By Formulation: Subcutaneous Injectable, Pre-Filled Syringes
3) By Distribution Channel: Retail Pharmacies, Online Pharmacies
4) By End User: Hospital, Clinicals, Ambulatory Care
What Trends Are Impacting The Sogroya Market?
Leading companies in the sogroya market are increasingly concentrating on obtaining regulatory authorizations to broaden the product’s indications and enhance its availability. Regulatory approvals refer to the official permission granted by government bodies to ensure a drug’s safety, effectiveness, and quality before it can be commercialized or prescribed. For instance, in April 2023, Novo Nordisk A/S, a Denmark-based pharmaceutical company, secured U.S. Food and Drug Administration (FDA) approval for Sogroya. This drug is intended for the treatment of children aged 2.5 years and older with growth hormone deficiency, establishing it as the first once-weekly growth hormone therapy available for both pediatric and adult patients. This innovative treatment allows for subcutaneous injection just once a week, offering a more convenient alternative to daily injections. The approval is founded on the phase 3 REAL4 study, which showed comparable height velocity results between Sogroya and traditional daily somatropin. Common adverse effects reported include nasopharyngitis, headache, and injection site reactions.
Which Organizations Are Involved In The Sogroya Market?
Major companies operating in the sogroya market are Novo Nordisk A/S
Access The Complete Sogroya Market Report:
https://www.thebusinessresearchcompany.com/report/sogroya-global-market-report
Which Region Is The Dominant Market In The Sogroya Market?
North America was the largest region in the sogroya market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sogroya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model